Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             279 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer Iaffaioli, R.V.
 1996
 32 Supplement 5 p. 1901-1904
4 p.
 artikel
2 Adaptation of the cellscan technique for the SCM test in breast cancer Rahmani, H.
 1996
 32 Supplement 5 p. 1758-1765
8 p.
 artikel
3 Adjuvant tamoxifen: 5 year control of dormant disease? Merimsky, O.
 1996
 32 Supplement 5 p. 174-
1 p.
 artikel
4 A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy 1996
 32 Supplement 5 p. 807-813
7 p.
 artikel
5 A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer Van Cutsem, E.
 1996
 32 Supplement 5 p. S23-S27
5 p.
 artikel
6 Alteration in mucin gene expression and biological properties of HT29 colon cancer cell subpopulations Kitamura, H.
 1996
 32 Supplement 5 p. 1788-1796
9 p.
 artikel
7 An image analysis study of DNA content in early colorectal cancer Kay, E.W.
 1996
 32 Supplement 5 p. 612-616
5 p.
 artikel
8 An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer? Chapman, J.W.
 1996
 32 Supplement 5 p. 1949-1956
8 p.
 artikel
9 An increased loading dose of ondansetron: a North European, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2 Brock, P.
 1996
 32 Supplement 5 p. 1744-1748
5 p.
 artikel
10 An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte macrophage-colony stimulating factor Bretti, S.
 1996
 32 Supplement 5 p. 1171-1178
8 p.
 artikel
11 Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies Tosi, E.
 1996
 32 Supplement 5 p. 498-505
 artikel
12 A phase II study of dacarbazine, cisplatin, interferon-α and high-dose interleukin-2 in ‘poor-risk’ metastatic melanoma Proebstle, T.M.
 1996
 32 Supplement 5 p. 1530-1533
4 p.
 artikel
13 A Phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer Ychou, M.
 1996
 32 Supplement 5 p. 1933-1937
5 p.
 artikel
14 A randomised study comparing granulocyte-coiony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy Sanchiz, F.
 1996
 32 Supplement 5 p. 52-56
5 p.
 artikel
15 A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb Lingam, M.K.
 1996
 32 Supplement 5 p. 1668-1673
6 p.
 artikel
16 211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage Link, E.M.
 1996
 32 Supplement 5 p. 1986-1994
9 p.
 artikel
17 Author index 1996
 32 Supplement 5 p. 61-66
6 p.
 artikel
18 Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: In vitro synergistic cytotoxicity and dna-induced strand-breaks Andreuccetti, M.
 1996
 32 Supplement 5 p. 1219-1226
8 p.
 artikel
19 Calendar of forthcoming meetings 1996
 32 Supplement 5 p. I-III
nvt p.
 artikel
20 Calendar of forthcoming meetings 1996
 32 Supplement 5 p. 741-747
7 p.
 artikel
21 Cancer: A challenge for control theory and computer modelling Düchting, W.
 1996
 32 Supplement 5 p. 1283-1292
10 p.
 artikel
22 Carcinoid of the pancreas: Clinical characteristics and morphological features Maurer, C.A.
 1996
 32 Supplement 5 p. 1109-1116
8 p.
 artikel
23 Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC breast group study Tomiak, E.
 1996
 32 Supplement 5 p. 1876-1887
12 p.
 artikel
24 Characterisation of platelet aggregation induced by PC-3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin Swaim, M.W.
 1996
 32 Supplement 5 p. 715-721
7 p.
 artikel
25 Chemotherapy of high-grade gliomas: Beginning of a new era or the end of the old? Brada, M.
 1996
 32 Supplement 5 p. 2193-2194
2 p.
 artikel
26 Clinical features, frequency and prognosis of Dukes' A colorectal carcinoma: A population-based investigation Di Gregorio, C.
 1996
 32 Supplement 5 p. 1957-1962
6 p.
 artikel
27 Colorectal Cancer: The Challenge Bleiberg, H.
 1996
 32 Supplement 5 p. S2-S6
5 p.
 artikel
28 Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours Taal, B.G.
 1996
 32 Supplement 5 p. 1924-1932
9 p.
 artikel
29 Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer Roca, E.
 1996
 32 Supplement 5 p. 429-432
 artikel
30 Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer Olver, I.N.
 1996
 32 Supplement 5 p. 249-254
6 p.
 artikel
31 Continuing medical education in oncology in europe Armand, J.P.
 1996
 32 Supplement 5 p. 1296-1299
4 p.
 artikel
32 Contribution of cervical ultrasound and ultrasound fineneedle aspiration biopsy to the staging of thoracic oesophageal carcinoma Bonvalot, S.
 1996
 32 Supplement 5 p. 893-895
3 p.
 artikel
33 Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma Karlsson, M.
 1996
 32 Supplement 5 p. 357-362
6 p.
 artikel
34 Cost of Treating Advanced Colorectal Cancer: A Retrospective Comparison of Treatment Regimens † † Some of the data contained in this manuscript were not presented at the ECCO 8 meeting. Ross, P.
 1996
 32 Supplement 5 p. S13-S17
5 p.
 artikel
35 CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer Saltz, L.
 1996
 32 Supplement 5 p. S24-S31
8 p.
 artikel
36 Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the milan cancer institute Bonadonna, G.
 1996
 32 Supplement 5 p. 209-214
6 p.
 artikel
37 Current Status of Colorectal Cancer: CPT-11 (Irinotecan), a Therapeutic Innovation Cunningham, D.
 1996
 32 Supplement 5 p. S1-S8
8 p.
 artikel
38 Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas Hagel, C.
 1996
 32 Supplement 5 p. 2242-2248
7 p.
 artikel
39 Development of Treatment for Advanced Colorectal Cancer: Infusional 5-FU and the Role of New Agents Schmoll, H.-J.
 1996
 32 Supplement 5 p. S18-S22
5 p.
 artikel
40 Differential responsiveness of proliferation and cytokeratin release to stripped serum and oestrogen in the human breast cancer cell line, MCF-7 Tedone, T.
 1996
 32 Supplement 5 p. 849-856
8 p.
 artikel
41 Direct gene transfer of a plasmid carrying the Herpes Simplex Virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: In vivo study Soubrane, C.
 1996
 32 Supplement 5 p. 691-695
5 p.
 artikel
42 Does age at the last birth affect breast cancer risk? Hsieh, C.-C.
 1996
 32 Supplement 5 p. 118-121
4 p.
 artikel
43 Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies Comella, P.
 1996
 32 Supplement 5 p. 1719-1726
8 p.
 artikel
44 Early detection of familial ovarian cancer Dørum, A.
 1996
 32 Supplement 5 p. 1645-1651
7 p.
 artikel
45 Effect of intracellular acidity and ionomycin on apoptosis in HL-60 Cells Park, H.J.
 1996
 32 Supplement 5 p. 540-546
 artikel
46 Effect of regional angiotensin ii infusion on the relationship between tumour blood flow and fluorouracil uptake in a liver metastasis animal model Dworkin, M.J.
 1996
 32 Supplement 5 p. 1580-1584
5 p.
 artikel
47 Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro Seckl, M.J.
 1996
 32 Supplement 5 p. 342-345
4 p.
 artikel
48 Efficacy of CPT-11 (Irinotecan) as a Single Agent in Metastatic Colorectal Cancer Shimada, Y.
 1996
 32 Supplement 5 p. S13-S17
5 p.
 artikel
49 Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro Seelig, M.H.
 1996
 32 Supplement 5 p. 1968-1976
9 p.
 artikel
50 Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C Berger, C.
 1996
 32 Supplement 5 p. 1707-1711
5 p.
 artikel
51 EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group Dirix, L.Y.
 1996
 32 Supplement 5 p. 2019-2022
4 p.
 artikel
52 Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining Thorban, S.
 1996
 32 Supplement 5 p. 363-365
3 p.
 artikel
53 Etoposide for the treatment of paediatric tumours: What is the best way to give it? Lowis, S.P.
 1996
 32 Supplement 5 p. 2291-2297
7 p.
 artikel
54 Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers In vitro and In vivo Tanaka, M.
 1996
 32 Supplement 5 p. 226-230
5 p.
 artikel
55 Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration Desoize, B.
 1996
 32 Supplement 5 p. 1734-1738
5 p.
 artikel
56 Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer Schuster-Uitterhoeve, A.L.J.
 1996
 32 Supplement 5 p. 1314-1319
6 p.
 artikel
57 Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial Viscoli, C.
 1996
 32 Supplement 5 p. 814-820
7 p.
 artikel
58 Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines Zaffaroni, N.
 1996
 32 Supplement 5 p. 1766-1773
8 p.
 artikel
59 5-fluorouracil cardiotoxicity: A unique mechanism for ischaemic cardiopathy and cardiac failure? Lieutaud, T.
 1996
 32 Supplement 5 p. 368-369
2 p.
 artikel
60 Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung Cancer Shipman, R.
 1996
 32 Supplement 5 p. 335-341
7 p.
 artikel
61 High-dose melphalan with re-infusion of unprocessed, G-CFS-primed whole blood is effective and non-toxic therapy in multiple myeloma Ossenkoppele, G.J.
 1996
 32 Supplement 5 p. 2058-2063
6 p.
 artikel
62 High frequency of urothelial cancers in patients with kidney transplantations for end-stage analgesic nephropathy Bokemeyer, C.
 1996
 32 Supplement 5 p. 175-176
2 p.
 artikel
63 Human papilloma virus has no prognostic significance in cervical carcinoma Kristensen, G.B.
 1996
 32 Supplement 5 p. 1349-1353
5 p.
 artikel
64 Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 °C whole body hyperthermia in patients with refractory sarcoma Wiedemann, G.J.
 1996
 32 Supplement 5 p. 888-892
5 p.
 artikel
65 Inadequacy of iridium implant as sole radiation treatment for operable breast cancer Fentiman, I.S.
 1996
 32 Supplement 5 p. 608-611
4 p.
 artikel
66 Information about diagnosis and prognosis related to anxiety and depression in children with cancer aged 8–16 years Last, B.F.
 1996
 32 Supplement 5 p. 290-294
5 p.
 artikel
67 International cancer news 1996
 32 Supplement 5 p. 749-752
4 p.
 artikel
68 International cancer news 1996
 32 Supplement 5 p. 1273-1278
6 p.
 artikel
69 In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin Belvedere, G.
 1996
 32 Supplement 5 p. 2011-2018
8 p.
 artikel
70 In Vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells Luparello, C.
 1996
 32 Supplement 5 p. 702-707
6 p.
 artikel
71 In vitro induction of differentiation by ginsenosides in F9 teratocarcinoma cells Lee, Y.-N.
 1996
 32 Supplement 5 p. 1420-1428
9 p.
 artikel
72 Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? de Takats, P.G.
 1996
 32 Supplement 5 p. 2201-2205
5 p.
 artikel
73 Isolated axillary recurrences after conservative treatment of breast cancer Renolleau, C.
 1996
 32 Supplement 5 p. 617-621
5 p.
 artikel
74 Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma Penna, C.
 1996
 32 Supplement 5 p. 1117-1122
6 p.
 artikel
75 MDR1 gene expression: Evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas Stein, U.
 1996
 32 Supplement 5 p. 86-92
7 p.
 artikel
76 Measuring the meaning of life for patients with incurable cancer: The life evaluation questionnaire (LEQ) Salmon, P.
 1996
 32 Supplement 5 p. 755-760
6 p.
 artikel
77 Men at higher sun-risk than women: Health message needs to be made 1996
 32 Supplement 5 p. 2190-
1 p.
 artikel
78 Modulated 5-Fluorouracil (5-FU) Regimens in Advanced Colorectal Cancer: A Critical Review of Comparative Studies Labianca, R.
 1996
 32 Supplement 5 p. S7-S12
6 p.
 artikel
79 Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors Mester, J.
 1996
 32 Supplement 5 p. 1603-1608
6 p.
 artikel
80 Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers Boer, R.
 1996
 32 Supplement 5 p. 857-861
5 p.
 artikel
81 Modulation of toxicity following external beam irradiation preceded by high-dose rate brachytherapy in inoperable oesophageal cancer Taal, B.G.
 1996
 32 Supplement 5 p. 1815-1818
4 p.
 artikel
82 MSH2 sequence variations and inherited colorectal cancer susceptibility Froggatt, N.J.
 1996
 32 Supplement 5 p. 178-
1 p.
 artikel
83 New aromatase inhibitors: More selectivity, less toxicity, unfortunately, the same activity Castiglione-Gertsch, M.
 1996
 32 Supplement 5 p. 393-395
 artikel
84 N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma Doz, F.
 1996
 32 Supplement 5 p. 645-649
5 p.
 artikel
85 No age limit for radical radiotherapy in head and neck tumours Pignon, T.
 1996
 32 Supplement 5 p. 2075-2081
7 p.
 artikel
86 79 O - An approach for evaluating the cost-effectiveness and impact on quality of life of inpatient treatment versus outpatient trea1ment during consolidation chemotherapy in elderly patients with acute myeloid leukemia (AML) Kiebert, W.
 1996
 32 Supplement 5 p. S15-
1 p.
 artikel
87 157 O - A new approach to refractory carcinoma of the prostate: microtubular inhibition with estramustine and vinorelbin Morgia, Giuseppe
 1996
 32 Supplement 5 p. S31-
1 p.
 artikel
88 163 O - Aortic infuslon (ADM, MMC, CDDP) and stop-flow (MMC, ADM) for systemically pretreated and progresslve FLGO III c and IV ovarian cancer-45 patients Gailhofer, S.
 1996
 32 Supplement 5 p. S32-
1 p.
 artikel
89 122 O - A phase I trial of epirubicin (E) and paclitaxel (P) in patients with metastatic breast cancer (MBC) Salyadori, R.
 1996
 32 Supplement 5 p. S24-
1 p.
 artikel
90 177 O - A prospective randomized trial on neoadjuvant and adjuvant chemo- and radiotherapy in primarily inoperable soft tissue sarcoma Zielinski, C.C.
 1996
 32 Supplement 5 p. S35-
1 p.
 artikel
91 117 O - Axillary node sampling in breast cancer: an assessment of its efficacy Ravi Sekar, O.
 1996
 32 Supplement 5 p. S23-
1 p.
 artikel
92 113 O - Conservative treatment of early breast cancer Paroconnaya, A.
 1996
 32 Supplement 5 p. S22-
1 p.
 artikel
93 138 O - Detection of colorectal carcinoma metastases in blood Denis, M.G.
 1996
 32 Supplement 5 p. S27-
1 p.
 artikel
94 35 O Does neoadjuvant npv (nitomycin c, cisplatin. vinblastine) chemothbrapy increase to risk of bronchopleural fistulas? Chiesa, G.
 1996
 32 Supplement 5 p. S7-
1 p.
 artikel
95 124 o - Does timing of surgery for breast cancer affect prognosis? Skuladottir, H.
 1996
 32 Supplement 5 p. S24-
1 p.
 artikel
96 147 O - Effect of preoperative hyperthermia with radio-chemo-therapy on resectability of locally advanced rectal cancer. A phase II clinical Rau, B.
 1996
 32 Supplement 5 p. S28-
1 p.
 artikel
97 181 O - HIV-related cervical cancer (CA) in Italy; a report of 54 cases from the Italian cooperative group on aids and tumors (GICAT) Santarossa, S.
 1996
 32 Supplement 5 p. S37-
1 p.
 artikel
98 137 O - Induction of a heat shock response protects tumour cells from monocyte mediated lysis Campbell, F.
 1996
 32 Supplement 5 p. S27-
1 p.
 artikel
99 143 O - Inoperable liver metastases from colo-rectal cancer treated by systemic or loco-regional chemotherapy Massidda, B.
 1996
 32 Supplement 5 p. S28-
1 p.
 artikel
100 154 O - Intermediate analysis at minimum 5 years follow-up of 70 patients with prostate cancer treated by external beam and brachytherapy Galalae, R.
 1996
 32 Supplement 5 p. S30-
1 p.
 artikel
101 153 O - In vitro electromotive administration of mitomycin C in human bladder wall Di Stasi, S.M.
 1996
 32 Supplement 5 p. S30-
1 p.
 artikel
102 50 O - Loss of heterozygosity (LOH) AT 5q21 and prognosis in resected non-small cell lung cancer (NSCLC) Sánchez, M.
 1996
 32 Supplement 5 p. S10-
1 p.
 artikel
103 68 O - Maintenance low-dose (LD) oral idarubicin (oIDA) in elderly patients (pts) with acute myelogeneous leukemia (AML) Musso, M.
 1996
 32 Supplement 5 p. S14-
1 p.
 artikel
104 140 O - Molecular analysis of APC mutations in familial adenomatous polyposis De Rosa, M.
 1996
 32 Supplement 5 p. S27-
1 p.
 artikel
105 20 O - Oxaliplatin (L-OHP) in fluorouracil (FU) refractory patients with metastallc colorectal cancer Nolè, F.
 1996
 32 Supplement 5 p. S5-
1 p.
 artikel
106 133 O - Prognostic significance of the nm23-H1 protein expression in colorectal cancer Abad, A.
 1996
 32 Supplement 5 p. S26-
1 p.
 artikel
107 162 O Randomized study of cyclophosphamide, doxorubicin & cisplatin (CAP) vs single agent carboplatin in ovarian cancer patients requiring chemotherapy: Interim results of ICON2 Crook, A.
 1996
 32 Supplement 5 p. S32-
1 p.
 artikel
108 3 O - Reentry into the cell cycle of live-irradiated quiescent normal human diploid fibroblasts: its relationships with p53 induction or inhibition Cćraline, J.
 1996
 32 Supplement 5 p. S1-
1 p.
 artikel
109 7 O - Relationship to multidrug resistance of the transporter associated with antigen presentation tap. Izquierdo, M.A.
 1996
 32 Supplement 5 p. S2-
1 p.
 artikel
110 74 O - Selective anti-leukemic potential of HLA-incompatible bone marrow transplants Ruggeri, Loredana
 1996
 32 Supplement 5 p. S15-
1 p.
 artikel
111 106 O - Sitam-01 adjuvant breast trial for patients > 50 years Belfiglio, M.
 1996
 32 Supplement 5 p. S21-
1 p.
 artikel
112 58 O - Successful engraftment of t-cell-depleted HLA-incompatible transplants Aversa, F.
 1996
 32 Supplement 5 p. S12-
1 p.
 artikel
113 98 O - Tamoxifen +/- short-term chemotherapy in the treatment of node positive, hormone receptor positive breast cancer: 7-year results of a randomized trial including 517 patients Jakesz, R.
 1996
 32 Supplement 5 p. S20-
1 p.
 artikel
114 51 O The alpi trial: a randomized study of adjuvant chemotherapy for stage I-II-IIIA non-small cell lung cancer (NSCLC) Scagliotti, G.
 1996
 32 Supplement 5 p. S10-
1 p.
 artikel
115 46 O - The role of vats (videothoracoscopy) in the staging of lung cancer Manzini, L.
 1996
 32 Supplement 5 p. S9-
1 p.
 artikel
116 134 O - The S.M.A.C. study: large scale collaborative trial of adjuvant therapy in colon cancer Alexanian, A.
 1996
 32 Supplement 5 p. S26-
1 p.
 artikel
117 21 O - Treatment of pig experimental cholangiocarcinoma by 5-fluoro-2-deoxyuridine conjugates: a comparative study Dufek, V.
 1996
 32 Supplement 5 p. S5-
1 p.
 artikel
118 161 O - Very high-dose chemotherapy (VHDCT) with ematologic support in previously untreated advanced ovarian cancer (OVCA): preliminary results of a phase I-II study Benedetti-panici, P.
 1996
 32 Supplement 5 p. S32-
1 p.
 artikel
119 114 P - Aminoacylation of mitochondrial tRNA from breast cancer tissue Pasternak, K.
 1996
 32 Supplement 5 p. S22-
1 p.
 artikel
120 33 P - A model to assess cost-effectiveness of prophylaxis of febrile neutropenia Bussels, J.
 1996
 32 Supplement 5 p. S7-
1 p.
 artikel
121 36 P A phase II study of epirubicin in combination therapy of small cell lung cancer (SCLC) Damianov, D.
 1996
 32 Supplement 5 p. S8-
1 p.
 artikel
122 9 P - A Possible mechanism of P-glycoprotein regulation in P-388 leukaemia cells Kuznet sovs, SJ
 1996
 32 Supplement 5 p. S2-
1 p.
 artikel
123 178 P - A randomized trial of adjuvant treatment of soft tissue sarcomas by either radiotherapy or radiotherapy + ifosfamide, adriblastin and DTIC (IFADIC) intensified by the use of G-CSF Zielinski, C.
 1996
 32 Supplement 5 p. S36-
1 p.
 artikel
124 Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin Zoetmulder, F.A.N.
 1996
 32 Supplement 5 p. 1727-1733
7 p.
 artikel
125 130 P - Breast conservation without axillary dissection Zurrida, S.
 1996
 32 Supplement 5 p. S25-
1 p.
 artikel
126 88 P - Carboplatin, Etoposide Plus UFT Modulated By Orally Leucovorin Low Dose Schedule (FLEE) In Metastatic Breast Cancer (MBE) Danlels, M.
 1996
 32 Supplement 5 p. S18-
1 p.
 artikel
127 102 P - CEF ± G-CSF As primary chemotherapy (PCT) in ≥ 3cm breast cancer (BC) patients(PTS) Conti, F.
 1996
 32 Supplement 5 p. S20-
1 p.
 artikel
128 100 P - Cell Proliferation Of Breast Cancer as a Marker of Radio- and Chemoendocrine Sensibility Koshelev, S.V.
 1996
 32 Supplement 5 p. S20-
1 p.
 artikel
129 165 P - Chemotherapy in adyanced oyarian cancer Płuzańska, A.
 1996
 32 Supplement 5 p. S33-
1 p.
 artikel
130 16 P Chemotherapy induced emesis. management of early and delayed emesis in milder emetogenic regimens Barrenetxea, G.
 1996
 32 Supplement 5 p. S4-
1 p.
 artikel
131 39 P - Chemotherapy induced leukopenia as a predictor of response in small cell lung cancer (SCLC) Jereczek, B.
 1996
 32 Supplement 5 p. S8-
1 p.
 artikel
132 144 P - Colonoscopic characteristics of synchronious colorectal carcinomas Nagorni, A.
 1996
 32 Supplement 5 p. S28-
1 p.
 artikel
133 139 P - Combined radiochemotherapy in patients with locally advanced pancreatic cancer (PC) Hejna, M.
 1996
 32 Supplement 5 p. S27-
1 p.
 artikel
134 182 P - Epirubicin, bleomycin, vinblastine and prednisone (EBVP) chemotherapy (CT) in combination with antiretroviral therapy and primary use of G-CSF for patients (pts) with hodgkin's disease and HIV infection (HD-HIV) Tirelli, U.
 1996
 32 Supplement 5 p. S37-
1 p.
 artikel
135 81 P - Epirubicin (EPI) + navelbine (NVB) as first line chemotherapy in advanced breast cancer (ABC) patients (PTS): a multicentric phase II study Baldini, E.
 1996
 32 Supplement 5 p. S17-
1 p.
 artikel
136 128 P - Epirubicin intermediate dose plus cyclophosphamide in the treatment of metastatic breast cancer (MBC) Trotti, G.
 1996
 32 Supplement 5 p. S25-
1 p.
 artikel
137 150 P - Expression of the drug resistance genes MDR1, MRP, GSTπ and MT2A in human primary gastric carcinomas Suchomel, R.W.
 1996
 32 Supplement 5 p. S29-
1 p.
 artikel
138 146 P - Familiarity and counselling in hereditary colorectal cancer Pozzi, S.
 1996
 32 Supplement 5 p. S28-
1 p.
 artikel
139 136 P - Feasibility and activity of a 3-day pelf-like regimen in advanced gastric cancer. Preliminary data Crivellari, D.
 1996
 32 Supplement 5 p. S27-
1 p.
 artikel
140 11 P - Frequent Loss of Heterozygosity at 6q in Malignant Salivary Gland Tumors Queimado, L.
 1996
 32 Supplement 5 p. S3-
1 p.
 artikel
141 49 P - Frequent replication errors at microsatellite loci on chromosomes 2p and 3p in non-small cell lung cancer Pifarré, A.
 1996
 32 Supplement 5 p. S10-
1 p.
 artikel
142 29 P - Gemcitabine: an active well tolerated drug for advanced non small cell lung cancer (NSCLC) de Braud, F.
 1996
 32 Supplement 5 p. S6-
1 p.
 artikel
143 169 P - Glutatiflon (GSH) for protection of cisplatinum (CDDP) induced neuro- and nephrotoxicity Djavanmard, M.P.
 1996
 32 Supplement 5 p. S34-
1 p.
 artikel
144 Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: A French cancer centre multicentric study Iliadis, A.
 1996
 32 Supplement 5 p. 455-460
 artikel
145 Phase II trial of N-(phosphonacetyl)-l-aspartate (PALA), 5-fluorouracil and recombinant interferon-α-2b in patients with advanced gastric carcinoma Wadler, S.
 1996
 32 Supplement 5 p. 1254-1256
3 p.
 artikel
146 Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer Klaassen, U.
 1996
 32 Supplement 5 p. 547-549
 artikel
147 Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF Ford, P.A.
 1996
 32 Supplement 5 p. 631-635
5 p.
 artikel
148 121 P - Hepatosteatosis and alterations of CA15.3 and CEA in patients with breast cancer receiving tamoxifen Sahin, B.
 1996
 32 Supplement 5 p. S24-
1 p.
 artikel
149 Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro Riesenberg, R.
 1996
 32 Supplement 5 p. 328-334
7 p.
 artikel
150 53 P - Ifosfamide, cisplatin and etoposide (ICE) combination in locally advanced non small cell lung cancer (NSCLC): a phase II study Scinto, A.F.
 1996
 32 Supplement 5 p. S10-
1 p.
 artikel
151 71 P - Immune profile in chronic lymphocytic leukemia Paydas, S.
 1996
 32 Supplement 5 p. S14-
1 p.
 artikel
152 31 P - Immunolymphoscintigraphy and sentinel node biopsy in melanoma Testori, A.
 1996
 32 Supplement 5 p. S6-
1 p.
 artikel
153 118 P - Indeterminate cytology in breast screening: correlation of mammography with histology Richards, P.J.
 1996
 32 Supplement 5 p. S23-
1 p.
 artikel
154 12 P - Interleukin-8 (IL-8), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), soluble tnf receptors (sTNFR) 75 and 55 after BCG therapy of urothelial cancer (TCC): kinetics over 6 instillations Thalmann, G.N.
 1996
 32 Supplement 5 p. S3-
1 p.
 artikel
155 5 P - Is P 53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancers? Eid, H.
 1996
 32 Supplement 5 p. S2-
1 p.
 artikel
156 40 P - Localized malignant mesothelioma in hungary Károlyi, A.
 1996
 32 Supplement 5 p. S8-
1 p.
 artikel
157 97 P - Low dose, short-term adjuvant chemotherapy in stage I hormone receptor negative breast cancer Jakesz, R.
 1996
 32 Supplement 5 p. S20-
1 p.
 artikel
158 63 P - Manual leukapheresis in life threatening blast transformation Dimitrijević, Gradimir
 1996
 32 Supplement 5 p. S13-
1 p.
 artikel
159 176 P - Measurement of stress dimension in cancer patients Siwek, B.
 1996
 32 Supplement 5 p. S35-
1 p.
 artikel
160 52 P - Mitomycin C. vlnorelbine. carboplatin and Gm-CSF for treatment of advanced non small cell lung carcinoma (NSCLC) Schenk, T.
 1996
 32 Supplement 5 p. S10-
1 p.
 artikel
161 73 P - Oral idarubicin (OIDA) in elderly patients (pts) with acute myelogenous Leukemia (AML): An opportunity? Visentin, F.C.A.
 1996
 32 Supplement 5 p. S14-
1 p.
 artikel
162 Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer Borner, M.M.
 1996
 32 Supplement 5 p. 2173-2176
4 p.
 artikel
163 Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the nishinihon cooperative study group of adjuvant chemoendocrine therapy for breast cancer (ACETBC) of Japan Morimoto, T.
 1996
 32 Supplement 5 p. 235-242
8 p.
 artikel
164 PP-5-18 adjuvant epirublcin and CMF +/− hormonotherapy in more than 3 nodes positive breast cancer patients: preliminary data de Matteis, A.
 1996
 32 Supplement 5 p. 37-38
2 p.
 artikel
165 PP-9-15 Analysis of angiogenesis, PCNA, c-er b B-2, and p53 associated with long-term survival in japanese women with breast cancer Kato, T.
 1996
 32 Supplement 5 p. 57-58
2 p.
 artikel
166 PP-3-12 Angiosarcomas of the breast after radiation for carcinoma: 3 new cases from Institut G Roussy Molitor, J.L.
 1996
 32 Supplement 5 p. 22-
1 p.
 artikel
167 PP-8-5 A randomised study assessing oestrogen suppression with arimidex™ (Anastrozole) and formestane in postmenopausal advanced breast cancer (ABC) patients Dowsett, M.
 1996
 32 Supplement 5 p. 49-50
2 p.
 artikel
168 PP-5-16 A Study of Postoperative Adjuvant Chemotherapy of 5′-DFUR in Breast Cancer Patients (1st Report) — On Compliance and Safety — “The 5′-BC Study Group” (5′-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group) Koyama, H.
 1996
 32 Supplement 5 p. 37-
1 p.
 artikel
169 PP-5-8 Atlas: An international megatrial of tamoxifen duration Davies, Christina
 1996
 32 Supplement 5 p. 36-
1 p.
 artikel
170 PP-2-25 Axillary clearance without drainage in breast cancer Stöckle, E.
 1996
 32 Supplement 5 p. 19-
1 p.
 artikel
171 PP-4-9 Breast cancer and in vitro fertilization Jourdain, O.
 1996
 32 Supplement 5 p. 28-
1 p.
 artikel
172 PP-6-22 Breast Cancer Outcome after Pregnancy Hallé, O.
 1996
 32 Supplement 5 p. 42-
1 p.
 artikel
173 PP-4-23 CA 15-3, CEA and TPS for Monitoring metastatic breast cancer patients — a multicenter study van Dalen, A.
 1996
 32 Supplement 5 p. 31-
1 p.
 artikel
174 PP-5-6 Castration and Tamoxifen Versus Chemotherapy (FAC) for Premenopausal, Node and Receptors Positive Breast Cancer Patients: A Randomized Trial with a 7 Years Median Follow Up Roché, H.
 1996
 32 Supplement 5 p. 35-
1 p.
 artikel
175 PP-1-17 Circulating tumor markers (CEA, MCA, CA 15.3, CA 549) in the diagnosis breast cancer recurrence after surgery: 5-Year results Zamagni, C.
 1996
 32 Supplement 5 p. 13-
1 p.
 artikel
176 PP-5-5 CMF vs Tamoxifen (TAM) Plus Goserelin (GOS) as Adjuvant Treatment of ER Positive (+VE) Pre-Perimenopausal Breast Cancer Patients (PTS). Preliminary Results of an Ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) Trial Boccardo, F.
 1996
 32 Supplement 5 p. 35-
1 p.
 artikel
177 PP-1-8 Cyclin D1 expression and response to tamoxifen treatment for metastatic breast cancer Barnes, D.M.
 1996
 32 Supplement 5 p. 11-
1 p.
 artikel
178 PP-1-19 Determination of cytosol ERBB-2 protein in primary breast cancer Imoto, S.
 1996
 32 Supplement 5 p. 13-
1 p.
 artikel
179 PP-5-10 Direct comparisons of adjuvant chemo-endocrine therapy in operable breast cancer stratified by ER and menopausal status Nomura, Y.
 1996
 32 Supplement 5 p. 36-
1 p.
 artikel
180 PP-5-4 Does Tamoxifen (Tam) increase bone resorption in premenopausal women? Bundred, N.J.
 1996
 32 Supplement 5 p. 35-
1 p.
 artikel
181 PP-7-6 Dose dense epirubicin (E) and paclitaxel (P) with G-CSF in metastatic breast cancer (MBC) Nortier, J.
 1996
 32 Supplement 5 p. 46-
1 p.
 artikel
182 PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) Smith, I.
 1996
 32 Supplement 5 p. 49-
1 p.
 artikel
183 PP-3-1 Ductal carcinoma in situ (dcis) of the breast: About 706 cases examined from 1971 to 1995 de Lara, C.Tunon
 1996
 32 Supplement 5 p. 20-
1 p.
 artikel
184 PP-7-3 Epirubicin (E) plus paclitaxel (P) in advanced breast cancer: A regimen with high activity and low cardiac toxicity which mobilizes peripheral blood stem cells Conte, P.F.
 1996
 32 Supplement 5 p. 45-
1 p.
 artikel
185 91 P - Periductal mastitis and mammary duct ectasia - two stages of the same disease? Diaconu, C.
 1996
 32 Supplement 5 p. S19-
1 p.
 artikel
186 PP-9-5 Expression of uPA, c-erbB2, EGF-R and p53 in 488 primary breast cancer Spyratos, F.
 1996
 32 Supplement 5 p. 56-
1 p.
 artikel
187 PP-5-14 FEC-75 Plus G-CSF in locally advanced breast carcinoma Artal, A.
 1996
 32 Supplement 5 p. 37-
1 p.
 artikel
188 170 P Phase II trial of lnterferon-γ (LFN-γ)/interleukln-2 (1L-2) for advanced renal cell carcinoma (RCC) Djavanmard, M.P.
 1996
 32 Supplement 5 p. S34-
1 p.
 artikel
189 PP-5-3 High dose chem otherapy (HDCT) with autologous blood cell (BC) Support in Metastatic Breast Cancer (MBC) Glück, S.
 1996
 32 Supplement 5 p. 35-
1 p.
 artikel
190 PP-5-17 High-dose cyclophosphamide (CTX), Mitoxantrone (MXT), and Paclitaxel (Taxol®, TXL) for the treatment of metastatic breast cancer (MBC) with blood cell support Glück, S.
 1996
 32 Supplement 5 p. 37-
1 p.
 artikel
191 PP-5-11 High dose mitoxantrone and cyclophosphamide with GM-CSF in first line chemotherapy of breast cancer Astone, A.
 1996
 32 Supplement 5 p. 36-
1 p.
 artikel
192 PP-6-12 Histopathological characteristics of ductal carcinoma in situ (DCIS) of the breast. A comparison before and after the introduction of mammographic screening Idvall, I.
 1996
 32 Supplement 5 p. 40-
1 p.
 artikel
193 PP-2-5 immediate breast reconstruction after mastectomy for cancer Ringberg, A.
 1996
 32 Supplement 5 p. 15-
1 p.
 artikel
194 PP-5-9 Impact of adjuvant chemotherapy in conservative treatment of breast cancer T1-2NOMO Semiglazov, V.F.
 1996
 32 Supplement 5 p. 36-
1 p.
 artikel
195 PP-5-19 Intensification chemotherapy (IQ) with autologous peripheral blood progenitor cell (PBPC) support in patients with breast cancer: Results of the transplantation procedure Constenia, M.
 1996
 32 Supplement 5 p. 38-
1 p.
 artikel
196 PP-5-12 Intensive chemotherapy program with autologous bone marrow transplantation (ABMT) in non metastatic inflammatory breast cancer: Mature results Roche, H.
 1996
 32 Supplement 5 p. 36-
1 p.
 artikel
197 PP-5-7 Interest of irradiation and AVCF chemotherapy in 241 Node-positive stage ii breast cancers: Late results Charrier, S.
 1996
 32 Supplement 5 p. 35-
1 p.
 artikel
198 PP-10-5 Involving a trained psychologists at the time of breast cancer (BC) surgery: Effects on communication and psychosocial adjustment Aimont, M.
 1996
 32 Supplement 5 p. 59-
1 p.
 artikel
199 PP-2-1 Localisation of impalpable breast lesions — a surgical approach Rovere, G.Querci della
 1996
 32 Supplement 5 p. 14-
1 p.
 artikel
200 PP-8-18 Long-term palliation of metastatic bone pain with intermittent pamidronate Zekri, I.
 1996
 32 Supplement 5 p. 52-
1 p.
 artikel
201 PP-8-30 MRF (Mitomycin, folinic acid and 5FU) for metastatic breast cancer — A prospective pilot study Lange, O.F.
 1996
 32 Supplement 5 p. 54-
1 p.
 artikel
202 PP-5-2 Neo-Adjuvant High-Dose FEC Regimen (H-FEC) with G-CSF (G) for Large Early Breast Cancer Llombart Cussac, A.
 1996
 32 Supplement 5 p. 34-
1 p.
 artikel
203 PP-7-18 Paclitaxel combinations with weekly high dose 5-FU/Folinic acid and cisplatin in the treatment of metastatic breast cancer — there is a possible role of combining paclitaxel with anthracycline non cross resistant chemotherapeutic agents in the first and second line treatment I Klaassen, U.
 1996
 32 Supplement 5 p. 48-
1 p.
 artikel
204 PP-7-5 phase II study of paclitaxel (P) and eplrubicin (E) as first-line therapy in patients (PTS) with metastatic breast cancer (MBC) Thomssen, Ch.
 1996
 32 Supplement 5 p. 46-
1 p.
 artikel
205 PP-5-15 Postoperative adjuvant randomized trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with Stage II breast cancer Morimoto, T.
 1996
 32 Supplement 5 p. 37-
1 p.
 artikel
206 PP-1-24 Prediction of the effect of 5′-deoxy-5-fluorouridine (5′-DFUR) by the status of angiogenic enzyme thymidine phosphorylase expression in advanced breast cancer patients Tominaga, T.
 1996
 32 Supplement 5 p. 14-
1 p.
 artikel
207 PP-5-1 Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer Rutgers, E.J.Th.
 1996
 32 Supplement 5 p. 34-
1 p.
 artikel
208 PP-4-5 Prognosis in patients with carcinoma in situ of the breast. A population based study in Sweden Wärnberg, F.
 1996
 32 Supplement 5 p. 27-28
2 p.
 artikel
209 PP-1-5 Quantitative determination of c.erbB.2 oncoprotein in 1065 human breast tumours by an enzymoimmunoassay. Comparison with the clinico-biological parameters: A multicentric study Koscielny, S.
 1996
 32 Supplement 5 p. 10-11
2 p.
 artikel
210 PP-2-10 radical mastectomy by means of a periareolar incision followed by immediate reconstruction Figueira Fo, Antonio S.S.
 1996
 32 Supplement 5 p. 16-
1 p.
 artikel
211 PP-5-13 Radical radiotherapy and effects of tamoxifen in patients with histologically positive stumps after breast preservation operations Kusama, M.
 1996
 32 Supplement 5 p. 36-37
2 p.
 artikel
212 PP-3-5 Risk factors for local recurrence after breast-conserving treatment: Results of a multicentre case-control study 1996
 32 Supplement 5 p. 21-
1 p.
 artikel
213 145 P - Prognostic factors for stomach and colorectal cancer. The analysis from population - based cancer registry Pawlega, J.
 1996
 32 Supplement 5 p. S28-
1 p.
 artikel
214 4 P - Prognostic value of molecular alterations of p53 and K-ras genes in non-small cell lung cancer de Anta, J.M.
 1996
 32 Supplement 5 p. S1-
1 p.
 artikel
215 PP-9-2 The value of nm23 protein expression and tumor angiogenesis as a prognostic indicator in breast cancer of korean women Lee, E.S.
 1996
 32 Supplement 5 p. 55-
1 p.
 artikel
216 77 P - Pulmonary impairment in long-survivors of hodgkin's disease (HD) Sorarù, M.
 1996
 32 Supplement 5 p. S15-
1 p.
 artikel
217 PP-8-12 Unclear value of salvage chemotherapy after failure to first-tine 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen for metaatatic breafit cancer Gardin, G.
 1996
 32 Supplement 5 p. 51-
1 p.
 artikel
218 PP-4-27 Use of prevention modalities for breast cancer: survey on 2889 self-administrated questionnaires Caffo, O.
 1996
 32 Supplement 5 p. 31-
1 p.
 artikel
219 Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. feasibility, toxicity and long-term results of a phase II study Favaretto, A.
 1996
 32 Supplement 5 p. 2064-2069
6 p.
 artikel
220 Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer Carpelan-holmström, M.
 1996
 32 Supplement 5 p. 1156-1161
6 p.
 artikel
221 107 P - Results of a randomized adjuvant breast cancer trial comparing a conventional with a perioperative start of chemotherapy Michl, L.
 1996
 32 Supplement 5 p. S21-
1 p.
 artikel
222 Primary gastric non-Hodgkin's lymphoma stage IE and IIE Lybeert, M.L.M.
 1996
 32 Supplement 5 p. 2306-2311
6 p.
 artikel
223 Primary treatment in stage ii non-seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? Culine, S.
 1996
 32 Supplement 5 p. 1641-1644
4 p.
 artikel
224 Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas Sun, X.F.
 1996
 32 Supplement 5 p. 1963-1967
5 p.
 artikel
225 179 P - Second line chemotherapy in HIV-related non-hodgkin's lymphoma: Evidence of activity of a combination of VP16, mitoxantrone and prednimustine in relapsed patients Errante, D.
 1996
 32 Supplement 5 p. S37-
1 p.
 artikel
226 27 P - Second line chemotherapy with modulation of drug resistance in patients with advanced soft tissue sarcoma Michl, I.
 1996
 32 Supplement 5 p. S6-
1 p.
 artikel
227 pS2 Protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study Machado, J.-C.
 1996
 32 Supplement 5 p. 1585-1590
6 p.
 artikel
228 48 P - Surgery following neoadjuvant chemotherapy (cisplatin, vepesid) in locally advanced non-small cell lung cancer Paprota, K.
 1996
 32 Supplement 5 p. S10-
1 p.
 artikel
229 65 P - The prognostic relevance of the substages of pathological stage III hodgkin's disease (HD) and its clinico-therapeutic implications Magrini, S.M.
 1996
 32 Supplement 5 p. S13-
1 p.
 artikel
230 25 P The role of a cytoreductive surgery in nonseminomatus germ cell tumor patients with small retroperitoneal mass after induction cemoterapy Karpov, S.A.
 1996
 32 Supplement 5 p. S5-
1 p.
 artikel
231 47 P - The role of basic fibroblast growth factor (bFGF) in human non small cell lung cancer (NSCLC) Mohr, Th.
 1996
 32 Supplement 5 p. S9-
1 p.
 artikel
232 19 P - The side effects of paclitaxel in solid tumors Cypro, Petr
 1996
 32 Supplement 5 p. S4-
1 p.
 artikel
233 99 P - Treatment of advanced breast cancer with vinorelbine (VLB), fluorouracil (FU), l-leucovorin (LLV) and human granulocyte colony-stimulating factor (GCSF) Kornek, G.V.
 1996
 32 Supplement 5 p. S20-
1 p.
 artikel
234 174 P - Treatment, result and follow-up of jaw,s sarcomas krodotov, M.
 1996
 32 Supplement 5 p. S35-
1 p.
 artikel
235 105 P - Two intense adjuvant regimens in high risk breast cancer patients who received neoadjuvant Massidda, B.
 1996
 32 Supplement 5 p. S21-
1 p.
 artikel
236 p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment Barbareschi, M.
 1996
 32 Supplement 5 p. 2182-2183
2 p.
 artikel
237 Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients Aparicio, J.
 1996
 32 Supplement 5 p. 1739-1743
5 p.
 artikel
238 Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line Manzano, R.Gonzalez
 1996
 32 Supplement 5 p. 2136-2141
6 p.
 artikel
239 Reproducibility of histological diagnosis of breast lesions: Results of a panel in Italy Palli, D.
 1996
 32 Supplement 5 p. 603-607
5 p.
 artikel
240 Response Franceschi, S.
 1996
 32 Supplement 5 p. 2181-2182
2 p.
 artikel
241 Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: An EORTC GITCCG study Wagener, D.J.Th.
 1996
 32 Supplement 5 p. 1310-1313
4 p.
 artikel
242 Retinoic acid concentrations in patients with squamous cell carcinoma of the head and neck Wahlberg, P.
 1996
 32 Supplement 5 p. 366-367
2 p.
 artikel
243 Role of oxygen free radicals in cancer development Dreher, D.
 1996
 32 Supplement 5 p. 30-38
9 p.
 artikel
244 Role of soluble mediators in angiogenesis Bussolino, F.
 1996
 32 Supplement 5 p. 2401-2412
12 p.
 artikel
245 Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta Beuzeboc, P.
 1996
 32 Supplement 5 p. 369-370
2 p.
 artikel
246 Somatostatin receptor imaging in small cell lung cancer Berenger, N.
 1996
 32 Supplement 5 p. 1429-1431
3 p.
 artikel
247 Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma Guida, M.
 1996
 32 Supplement 5 p. 730-733
4 p.
 artikel
248 Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987 Gatta, G
 1996
 32 Supplement 5 p. 831-835
5 p.
 artikel
249 Superficial bladder cancer: Study of the proliferative nuclear fraction as a prognostic factor Blasco-Olaetxea, E.
 1996
 32 Supplement 5 p. 444-446
 artikel
250 Survival for colon and rectal cancer in a population-based cancer registry Roncucci, L.
 1996
 32 Supplement 5 p. 295-302
8 p.
 artikel
251 Survival in small intestinal adenocarcinoma Zar, N.
 1996
 32 Supplement 5 p. 2114-2119
6 p.
 artikel
252 SY-1-2 Genes predisposing to breast cancer Devilee, P.
 1996
 32 Supplement 5 p. 7-
1 p.
 artikel
253 SY-4-4 Immunohistochemistry as a tool for new prognostic markers Grogan, G.Mac
 1996
 32 Supplement 5 p. 25-
1 p.
 artikel
254 SY-1-1 Quality control in molecular pathology De Bortoli, Michele
 1996
 32 Supplement 5 p. 7-
1 p.
 artikel
255 SY-5-3 Results of the 1995 meta analysis Gray, R.
 1996
 32 Supplement 5 p. 26-
1 p.
 artikel
256 SY-5-1 Risk determination for good prognosis patients Namer, M.
 1996
 32 Supplement 5 p. 25-26
2 p.
 artikel
257 SY-5-2 Selection of treatment Pritchard, K.I.
 1996
 32 Supplement 5 p. 26-
1 p.
 artikel
258 SY-5-4 Trials in progress and trials now needed Senn, H.J.
 1996
 32 Supplement 5 p. 26-
1 p.
 artikel
259 The activity and expression of thymidine phosphorylase in human solid tumours Takebayashi, Y.
 1996
 32 Supplement 5 p. 1227-1232
6 p.
 artikel
260 The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line Johnston, P.G.
 1996
 32 Supplement 5 p. 2148-2154
7 p.
 artikel
261 The charing cross hospital experience with temozolomide in patients with gliomas Newlands, E.S.
 1996
 32 Supplement 5 p. 2236-2241
6 p.
 artikel
262 The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments Walker, L.G.
 1996
 32 Supplement 5 p. 2275-2283
9 p.
 artikel
263 The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer Evans, W.K.
 1996
 32 Supplement 5 p. 2249-2255
7 p.
 artikel
264 The management of retroperitoneal soft tissue sarcomas Jenkins, M.P.
 1996
 32 Supplement 5 p. 622-626
5 p.
 artikel
265 The marriage of pathology and genetics in soft tissue tumours: EACR—Mühlbock memorial lecture Van den Berghe, H.
 1996
 32 Supplement 5 p. 1849-1856
8 p.
 artikel
266 The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer Webb, A.
 1996
 32 Supplement 5 p. 63-68
6 p.
 artikel
267 The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853 da Silva, F.C.
 1996
 32 Supplement 5 p. 72-77
6 p.
 artikel
268 Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy Fauser, A.A.
 1996
 32 Supplement 5 p. 1523-1529
7 p.
 artikel
269 The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis van der Wall, E.
 1996
 32 Supplement 5 p. 1490-1497
8 p.
 artikel
270 Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia Buchholz, B.
 1996
 32 Supplement 5 p. 2101-2107
7 p.
 artikel
271 ‘Tomudex’ (ZD1694): Results of a Randomised Trial in Advanced Colorectal Cancer Demonstrate Efficacy and Reduced Mucositis and Leucopenia Cunningham, D.
 1996
 32 Supplement 5 p. 1945-1954
10 p.
 artikel
272 Treatment costs in hodgkin's disease: A cost-utility analysis Norum, J.
 1996
 32 Supplement 5 p. 1510-1517
8 p.
 artikel
273 Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects Geisler, J.
 1996
 32 Supplement 5 p. 789-792
4 p.
 artikel
274 Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines Hiss, D.
 1996
 32 Supplement 5 p. 2164-2172
9 p.
 artikel
275 Type C hepatitis and chronic lymphocytic leukaemia La Civita, L.
 1996
 32 Supplement 5 p. 1819-1820
2 p.
 artikel
276 Unknown primary carcinoma: Randomised studies are needed to identify optimal treatments and their benefits Farrugia, D.C.
 1996
 32 Supplement 5 p. 2256-2261
6 p.
 artikel
277 Upper age limit for cervical cancer screening Cecchini, S.
 1996
 32 Supplement 5 p. 180-
1 p.
 artikel
278 Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study Filella, X
 1996
 32 Supplement 5 p. 1125-1128
4 p.
 artikel
279 Vascular endothelial growth factor Ferrara, N.
 1996
 32 Supplement 5 p. 2413-2422
10 p.
 artikel
                             279 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland